Seeking male and female participants under the age of 25, who were diagnosed with Chronic Myeloid Leukemia before the age of 18, to determine if they can stop taking their TKI medication and remain in remission as well as if restarting TKI will re-achieve remission.
Seeking people aged 2-21 years who have been diagnosed with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive Acute Lymphoblastic Leukemia (ALL) for a study of whether using a less toxic chemotherapy in combination with a drug called imatinib can keep the cancer from returning after treatment.
Seeking children and young adults 31 years old or younger who have been newly diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B ALL or localized B-cell Lymphoblastic Lymphoma (B-LLy) for a study of chemotherapy.
Children and young adults up to age 25 with High-Risk B-cell acute lymphoblastic leukemia (B-ALL) sought for a study of an investigational drug in combination of chemotherapy based on individual disease characteristics to improve 5-year disease-free survival (DFS).
Seeking children and young adults whose CD22+ B-Acute Lymphoblastic Leukemia (B ALL) has come back (relapsed) after treatment or has not responded (refractory) for a study of an investigational drug. While the investigational drug has been approved for use adults with leukemia, it has not yet been approved for use in children.